Concepedia

Publication | Open Access

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

DOIFull Paper Access

114

Citations

21

References

2021

Year

Ola Landgren, Malin Hultcrantz, Benjamin Diamond, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Carlyn Tan, Urvi A. Shah, Sydney X. Lu, Meghan Salcedo,
JAMA Oncology

Abstract

In this nonrandomized clinical trial, carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy was associated with high rates of MRD negativity in patients with newly diagnosed multiple myeloma and high rates of PFS.

References

YearCitations

Page 1